To include your compound in the COVID-19 Resource Center, submit it here.

Tetravalent dengue vaccine: Phase III data

A double-blind, Latin American Phase III trial in 20,875 healthy children and adolescents ages 9-16 showed that 0.5 mL subcutaneous injections of Sanofi's tetravalent dengue vaccine given at 0,

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE